Genetic Screening for Cancer

Overseen by Kenneth Offit, MD, MPH

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

Trial Summary

What is the purpose of this trial?

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

Research Team

Kenneth Offit, MD, MPH

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for Ashkenazi Jewish individuals with a confirmed cancer diagnosis, including kidney, breast, colon, prostate, lung, ovarian, bladder cancers or lymphoid malignancies. Eligible participants must have donated a blood sample at MSKCC and can have multiple diagnoses of the same cancer type.

Inclusion Criteria

Samples ascertained as part of protocol 98-024A(1) are also eligible for ascertainment in this study.

I am of Ashkenazi Jewish descent and have been diagnosed with cancer.

I have cancer in one of the specified organs and have given a blood sample at MSKCC.

Exclusion Criteria

I do not have a confirmed diagnosis of cancer in specific organs or lymphoma for the AMDeC study part.

Treatment Details

Interventions

• PCR/PCR/LDR Strategy (Genetic Testing)

Trial Overview The study is exploring if there's a link between inherited genetic variations (germline polymorphisms) and various cancers using PCR/PCR/LDR strategy to analyze DNA. It aims to generate hypotheses for future research rather than test a treatment.

Participant Groups

Group I: 1 Active Control 1 Intervention

All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer "cases" and first primary "controls".

Group II: 2 Placebo Group 1 Intervention

Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University

Weill Medical College of Cornell University

Collaborator

Trials

1,103

Recruited

1,157,000+

Dr. Robert Min

Weill Medical College of Cornell University

Chief Executive Officer since 2024

MD, MBA

Dr. Adam R. Stracher

Weill Medical College of Cornell University

Chief Medical Officer since 2024

MD

Columbia University

Collaborator

Trials

1,529

Recruited

2,832,000+

Dr. Katrina Armstrong

Columbia University

Chief Executive Officer

MD from Johns Hopkins University, MS in Epidemiology from Harvard School of Public Health

Dr. Katrina Armstrong

Columbia University

Chief Medical Officer

MD from Harvard Medical School

Icahn School of Medicine at Mount Sinai

Collaborator

Trials

933

Recruited

579,000+

Dr. Brendan Carr

Icahn School of Medicine at Mount Sinai

Chief Executive Officer since 2024

MD, MA, MS

Dr. Vicki LoPachin

Icahn School of Medicine at Mount Sinai

Chief Medical Officer

MD, FACP, MBA